HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Sagimet Biosciences (NASDAQ:SGMT) and maintained a price target of $32.
May 16, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Sagimet Biosciences and maintained a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $32 by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Sagimet Biosciences, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100